What are the functions and effects of pemetinib and what is its price?

Pemigatinib (Pemigatinib), also known as pemetinib, is an innovative drug used to treat certain types of cholangiocarcinoma. It belongs to a class of drugs called "FGFR inhibitors" that inhibit the growth and division of cancer cells by inhibiting the fibroblast growth factor receptor (FGFR) pathway.

Pemetinib has shown remarkable results in the treatment of cholangiocarcinoma. Cholangiocarcinoma is a highly aggressive malignant tumor that is often difficult to detect in its early stages and is highly resistant to traditional treatments, so treatment has always been a huge challenge. The emergence of pemetinib has brought new treatment options to patients with cholangiocarcinoma. It is mainly targeted at patients with advanced cholangiocarcinoma whose disease has progressed despite chemotherapy or surgery, especially those with FGFR2 gene fusions or rearrangements.

The mechanism of action of pemetinib involves the inhibition of abnormal kinases. In cholangiocarcinoma, some patients have mutations or rearrangements of the FGFR gene, which leads to abnormal activation of FGFR kinase. Pemetinib inhibits tumor cell proliferation and growth by selectively inhibiting FGFR kinase and reducing abnormal signaling. Clinical trials have shown that a considerable number of patients with cholangiocarcinoma treated with pemetinib experienced partial or complete remission of their tumors. At the same time, the patients' survival period was also prolonged and their quality of life was improved.

Pemetinib is usually administered to patients in the form of oral medication once daily. The specific dosage and course of treatment should be adjusted according to the doctor's guidance and the patient's individual condition. However, although pemetinib has shown good efficacy in the treatment of cholangiocarcinoma, there are still some side effects, such as fatigue, nausea, vomiting, diarrhea, appetite changes, and weight loss. Patients need to pay close attention to side effects when receiving pemetinib treatment and communicate with their doctors in a timely manner.

In summary, pemetinib, as a targeted therapy, provides new treatment options and hope for patients with cholangiocarcinoma. It controls tumor growth and spread by inhibiting the activity of abnormal kinases, bringing better treatment effects and survival chances to cholangiocarcinoma patients.

Pemetinib has been launched in China, and patients can purchase this original drug directly in domestic hospitals. Its specifications areThe market price of 14 tablets of 4.5mg is about 30,000 yuan. It is understood that there are both original and generic versions on the foreign market. The original version of 13.5 mg and 14 tablets is priced at about 72,000 yuan, while the generic version of Lucius Pharmaceuticals in Laos only costs about 850 yuan with the same specifications. If you want to learn more about pemetinib, it is recommended to consult a regular overseas medical service institution.

xa0

Reference link: https://www.sciencedirect.com/science/article/abs/pii/S1525730423001961